The Efficacy of Computerized Cognitive Behavioral Therapy for Depressive and Anxiety Symptoms in Patients With COVID-19: Randomized Controlled Trial
Open accessPublished version of a preprint
The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index; 3 of the 26 sources its claims cite were checked for support.
Abstract
Background The prevalence of depressive and anxiety symptoms in patients with COVID-19 is higher than usual. Previous studies have shown that there are drug-to-drug interactions between antiretroviral drugs and antidepressants. Therefore, an effective and safe treatment method was needed. Cognitive behavioral therapy (CBT) is the first-line psychological therapy in clinical treatment. Computerized CBT (cCBT) was proven to be an effective alternative to CBT and does not require face-to-face therapy between a therapist and the patient, which suited the COVID-19 pandemic response. Objective This study aims to evaluate the efficacy of the cCBT program we developed in improving depressive and anxiety symptoms among patients with COVID-19. Methods We customized a cCBT program focused on improving depressive and anxiety symptoms among patients with COVID-19, and then, we assessed its effectiveness. Screening was based on symptoms of depression or anxiety for patients who scored ≥7 on the Hamilton Depression Rating Scale (HAMD17) or the Hamilton Anxiety Scale (HAMA). A total of 252 patients with COVID-19 at five sites were randomized into two groups: cCBT + treatment as usual (TAU; n=126) and TAU without cCBT (n=126). The cCBT + TAU group received the cCBT intervention program for 1 week. The primary efficacy measures were the HAMD17 and HAMA scores. The secondary outcome measures were the Self-Rating Depression Scale (SDS), Self-Rating Anxiety Scale (SAS), and Athens Insomnia Scale (AIS). Assessments were carried out pre- and postintervention. The patients’ symptoms of anxiety and depression in one of the centers were assessed again within 1 month after the postintervention assessment. Results The cCBT + TAU group displayed a significantly decreased score on the HAMD17, HAMA, SDS, SAS, and AIS after the intervention compared to the TAU group (all P<.001). A mixed-effects repeated measures model revealed significant improvement in symptoms of depression (HAMD17 and SDS scores, both P<.001), anxiety (HAMA and SAS scores, both P<.001), and insomnia (AIS score, P=.002) during the postintervention and follow-up periods in the cCBT + TAU group. Additionally, the improvement of insomnia among females (P=.14) and those with middle school education (P=.48) in the cCBT + TAU group showed no significant differences when compared to the TAU group. Conclusions The findings of this study suggest that the cCBT program we developed was an effective nonpharmacological treatment for symptoms of anxiety, depression, and insomnia among patients with COVID-19. Further research is warranted to investigate the long-term effects of cCBT for symptoms of anxiety, depression, and insomnia in patients with COVID-19. Trial Registration Chinese Clinical Trial Registry ChiCTR2000030084; http://www.chictr.org.cn/showprojen.aspx?proj=49952
Overview
CoChat Summary
## TL;DR
This multicenter randomized controlled trial found that a 1-week computerized CBT program added to treatment as usual reduced depressive, anxiety, and insomnia symptoms in patients with COVID-19 compared with treatment as usual alone. The benefits were seen immediately postintervention and were still present at 1-month follow-up in the subset assessed.
## Key findings
- Among 252 analyzable patients with COVID-19 randomized 1:1 to cCBT + TAU (n=126) or TAU (n=126), the cCBT + TAU group had significantly lower postintervention scores on all primary and secondary outcomes: HAMD17, HAMA, SDS, SAS, and AIS, all P<.001.
- In the repeated-measures analysis, the cCBT + TAU group showed significant improvement over postintervention and follow-up in depression (HAMD17 and SDS, both P<.001), anxiety (HAMA and SAS, both P<.001), and insomnia (AIS, P=.002).
- At 1-month follow-up, the interaction between group and period was significant for all five scales (all P<.001), and post hoc tests showed significant reductions from baseline in the cCBT + TAU group for all five scores (all P<.05, Bonferroni-adjusted).
- Subgroup analyses found no significant between-group improvement in insomnia for females (P=.14) or for patients with middle school education (P=.48).
## Methods
- Prospective, multicenter, nonblinded, two-arm, parallel-group randomized controlled trial conducted at five hospitals in China from March 2020 to June 2020.
- Eligible participants were adults 18–75 years with mild/common COVID-19 and mild to moderate depressive or anxiety symptoms, defined as HAMD17 ≥7 or HAMA ≥7; 252 participants were analyzed after screening.
- Participants were randomized 1:1 to 1 week of cCBT + TAU or TAU alone; main analyses used t tests, subgroup analyses, and a mixed-effects model for repeated measures (MMRM) with Bonferroni post hoc testing.
## Limitations
- The paper states the trial was nonblinded, and says this, together with multiple outcomes, increased the risk of type I error.
- The paper states the sample sizes were relatively small and the follow-up time was relatively short.
- The paper states it did not account for more confounding factors such as drug side effects and related adversity.
- Evident from the text: the 1-month follow-up was done in only one center, so longer-term generalizability is limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
2 Valid · 0 Not valid · 16 Not checked · 32 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CBT is the first-line psychological treatment recommended by the guidelines of depression, anxiety, and PTSD (ie, Canadian Network for Mood and Anxiety Treatments and National Institute of Health and Care Excellence guideline [49,50].”
§ The Efficacy of Computerized Cognitive Behavioral Therapy for Depressive and Anxiety Symptoms in Patients With COVID-19: Randomized Controlled Trial > Discussion > Principal Results
What the sources say
- Partly supportedcites [49] sourceExperimental — accuracy not yet measured
Our copy of CANMAT 2016 Section 2 fully supports the depression component: Table 5 lists CBT as first line for both acute treatment and relapse-prevention maintenance (Level 1), and section 2.10 states 'CBT has Level 1 Evidence and is recommended as a first-line maintenance therapy' as well as first-line for acute MDD. However, the Abstract states 'The scope of these guidelines remains the management of adults with unipolar major depressive disorder (MDD)', and no passage makes any first-line recommendation for anxiety disorders or PTSD; the only anxiety-related content is section 2.3, which summarises evidence on comorbid anxiety in depression ('insufficient evidence to define formal treatment recommendations'). The anxiety and PTSD components of the claim are therefore not supported by this source (they would rest on the companion NICE citation). (LLM, conf=0.85)
- Not checked yetcites [50] Post-traumatic stress disorderThe National Institute for Health and Care Excellence2020-12-15https://www.nice.org.uk/guidance/ng116
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Computerized CBT (cCBT) was proven to be an effective alternative to CBT and does not require face-to-face therapy between a therapist and the patient, which suited the COVID-19 pandemic response.”
- Also stated in: § Introduction · boosted
“There is substantial evidence that cCBT is an effective alternative to CBT for the treatment of mild to moderate depression and anxiety [18-20].”
§ The Efficacy of Computerized Cognitive Behavioral Therapy for Depressive and Anxiety Symptoms in Patients With COVID-19: Randomized Controlled Trial > Abstract > Background
What the sources say
- Partly supportedcites [18] sourceExperimental — accuracy not yet measured
The DISCUSSION (p. Results/Discussion) and abstract report the trial's core finding — noninferiority of clinician-supported CCBT versus a full 16-week/20-session standard CBT course in 154 drug-free patients with major depressive disorder, with comparable completion and remission rates (week 16 HAMD 8.9 vs 9.2, d=0.05) — which supports 'effective alternative to CBT' for depression. However, the population qualifiers are not supported: the METHODS exclusion criteria removed patients with a primary anxiety disorder, entry required HAMD ≥14, and RESULTS (Patient Characteristics) note nearly 50% scored ≥20 with over half chronic, so this is neither an anxiety study nor a mild-depression sample; the paper only cites meta-analyses (refs 20–24) for CCBT's broader efficacy. The citing sentence's added claim that cCBT 'does not require face-to-face therapy' runs against our copy, which states 'We only provided face-to-face therapist support in this investigation' (DISCUSSION) and that stand-alone unsupported programs 'typically have much smaller effects' with 'some amount of clinical support is important' (INTRODUCTION). (LLM, conf=0.78)
- Not checked yetcites [19] source
- Partly supportedcites [20] sourceExperimental — accuracy not yet measured
Our copy supports the anxiety half of the claim: the Abstract Conclusions and Discussion (post-treatment outcomes) report that both clinician- and technician-assisted iCBT for DSM-IV GAD gave large effect sizes (PSWQ 1.16/1.07; GAD-7 1.55/1.73) 'comparable to those associated with face-to-face treatment' and to meta-analyses of face-to-face CBT for GAD. It does not support the depression indication: depression was only a secondary measure (PHQ-9) in GAD participants, and the Methods (Participants) screened out people with severe depression rather than recruiting a 'mild to moderate depression' sample, so the paper is not evidence that cCBT is an effective alternative to CBT for depression. The claim's generalization across 'mild to moderate depression and anxiety' therefore exceeds this single GAD trial. (LLM, conf=0.75)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The cCBT + TAU group displayed a significantly decreased score on the HAMD17, HAMA, SDS, SAS, and AIS after the intervention compared to the TAU group (all P<.001).”
- Also stated in: § Results · plain
“Compared to the TAU group, the cCBT + TAU group showed significant improvement in both the primary outcomes of HAMD17 and HAMA scores and the secondary outcomes of SDS, SAS, and AIS scores (all P<.001).”
§ The Efficacy of Computerized Cognitive Behavioral Therapy for Depressive and Anxiety Symptoms in Patients With COVID-19: Randomized Controlled Trial > Abstract > Results
plainstates a causen = 252- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As demonstrated in Table 4, a significant difference in the interaction between groups and periods (all P<.001) was observed in all scale scores.”
§ The Efficacy of Computerized Cognitive Behavioral Therapy for Depressive and Anxiety Symptoms in Patients With COVID-19: Randomized Controlled Trial > Results
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Additionally, the improvement of insomnia among females (P=.14) and those with middle school education (P=.48) in the cCBT + TAU group showed no significant differences when compared to the TAU group.”
- Also stated in: § Results · plain
“For female patients, we found no evidence of significant between-group differences for the change of AIS scores (Table S1 in Multimedia Appendix 1).”
§ The Efficacy of Computerized Cognitive Behavioral Therapy for Depressive and Anxiety Symptoms in Patients With COVID-19: Randomized Controlled Trial > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
20 more claims
Create a free account to see all 50 claims and to verify the 23 references still open.
- The quote only partly states this claim. 1
- Probably not a substantial claim. 15
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Only the RCT on cCBT found reductions in depressive symptoms post-intervention [20].”
From Promoting Recovery from Disasters, Pandemics, and Trauma: A Systematic Review of Brief Psychological Interventions to Reduce Distress in Adults, Children, and Adolescents (2023) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both studies reported significant reductions in anxiety at one-month follow-up after the application of cCBT [20] and post-training after the application of the Individualized Short-term Training Program [21].”
From Promoting Recovery from Disasters, Pandemics, and Trauma: A Systematic Review of Brief Psychological Interventions to Reduce Distress in Adults, Children, and Adolescents (2023) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The intervention was tested in an RCT during the COVID-19 pandemic in China with N = 252 adult COVID-19-infected patients [20].”
The cited source says what the claim attributes to it.
In the citing paper
“A significant decrease in depressive and anxiety symptoms was found at one-month follow-up in the cCBT + treatment as usual (TAU) group compared to a TAU-only group”
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“For HAMD 17 [30], items are scored on a 5-point Likert scale (0-4) for a total score range from 0 to 68, with higher scores indicating more depressive symptoms.”
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · cited 1×
“COVID-19, caused by a novel coronavirus (SARS-CoV-2) [5], continues to spread worldwide.”
Self-citationThe assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455 · cited 1×
“Similarly, HAMA [31] consists of 14 items on a 5-point Likert scale (0-4) for a total score range from 0 to 56, with higher scores indicating more anxiety symptoms.”
The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
Rothan, H. A., & Byrareddy, S. N. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102433 · Cited by 5,840 · cited 1×
“…effects of physical and psychological distress have increased with each successive public health emergency, such as with the severe acute respiratory syndrome (SARS) in 2003 [1], the Middle East Respiratory Syndrome (MERS) [2] in 2012, the Ebola virus disease in 2014 [3], and COVID-19 in 2020 [4].”
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Moreover, only an approximate 33% of the patients were clinically cured [46], and these demonstrated residual symptoms following acute treatment [47].”
Guo (2020) · doi:10.1186/s40779-020-00240-0 · Cited by 4,735 · cited 1×
“The common clinical symptoms of patients with COVID-19 include cough, fever, fatigue, hypoxia, and occasionally gastrointestinal infection [12].”
WHO Coronavirus Disease (COVID-19) Dashboard
(2020) · Bangladesh Physiotherapy Journal · doi:10.46945/bpj.10.1.03.01 · Cited by 3,806 · cited 1×
“At present, there have been nearly 30 million confirmed cases and nearly 1 million deaths worldwide [7].”
Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed
Xiang, Y.-T., Yang, Y., Li, W., Zhang, L., Zhang, Q., Cheung, T., & Ng, C. H. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30046-8 · Cited by 3,598 · cited 2×
“…including but not limited to drug side effects, a fear of severe disease consequences, a fear of infecting others, and an inability to get correct information in a timely manner [13]—all of which may lead to several psychological distresses including anxiety, depression, and insomnia [8,14].”
Self-citationCOVID-19 pandemic and mental health consequences: Systematic review of the current evidence
Vindegaard, N., & Benros, M. E. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.05.048 · Cited by 3,221 · cited 1×
“Moreover, evidence from epidemiological studies revealed the relationship between gender, age, education level, and severity of mental problems [24].”
Velavan, T. P., & Meyer, C. G. (2020) · Tropical Medicine & International Health · doi:10.1111/tmi.13383 · Cited by 2,439 · cited 1×
“On January 30, 2020, the World Health Organization Emergency Committee declared a global health emergency based on growing case notification rates at Chinese and international locations [6].”
Rogers, J. P., Chesney, E., Oliver, D., Pollak, T. A., McGuire, P., Fusar-Poli, P., Zandi, M. S., Lewis, G., & David, A. S. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30203-0 · Cited by 2,407 · cited 1×
“[10].”
Prevalence of mental disorders in China: a cross-sectional epidemiological study
Huang, Y., Wang, Y., Wang, H., Liu, Z., Yu, X., Yan, J., Yu, Y., Kou, C., Xu, X., Lu, J., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30511-x · Cited by 2,335 · cited 1×
“A meta-analysis about the prevalence of mental health problems in patients with COVID-19 showed prevalence rates of depression at 15.97%, anxiety at 15.5%, PTSD at 21.94%, and insomnia at 23.87% [41]—all far higher than usual [42].”
InfluentialSelf-citationAthens Insomnia Scale: Validation of an instrument based on ICD-10 criteria
Soldatos, C. R., Dikeos, D. G., & Paparrigopoulos, T. J. (2000) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(00)00095-7 · Cited by 1,754 · cited 1×
“The last secondary outcome measure is AIS [34], a validated brief questionnaire for a total score range from 0 to 24”
The Severe Acute Respiratory Syndrome
Peiris, J. S. M., Yuen, K. Y., Osterhaus, A. D. M. E., & Stöhr, K. (2003) · New England Journal of Medicine · doi:10.1056/nejmra032498 · Cited by 1,346
Middle East respiratory syndrome
Zumla, A., Hui, D. S., & Perlman, S. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60454-8 · Cited by 1,263 · cited 1×
“…effects of physical and psychological distress have increased with each successive public health emergency, such as with the severe acute respiratory syndrome (SARS) in 2003 [1], the Middle East Respiratory Syndrome (MERS) [2] in 2012, the Ebola virus disease in 2014 [3], and COVID-19 in 2020 [4].”
Progression of Mental Health Services during the COVID-19 Outbreak in China
Li, W., Yang, Y., Liu, Z.-H., Zhao, Y.-J., Zhang, Q., Zhang, L., Cheung, T., & Xiang, Y.-T. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45120 · Cited by 1,213 · cited 1×
“…including but not limited to drug side effects, a fear of severe disease consequences, a fear of infecting others, and an inability to get correct information in a timely manner [13]—all of which may lead to several psychological distresses including anxiety, depression, and insomnia [8,14].”
Self-citationCénat, J. M., Blais-Rochette, C., Kokou-Kpolou, C. K., Noorishad, P.-G., Mukunzi, J. N., McIntee, S.-E., Dalexis, R. D., Goulet, M.-A., & Labelle, P. R. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2020.113599 · Cited by 952 · cited 1×
“A meta-analysis about the prevalence of mental health problems in patients with COVID-19 showed prevalence rates of depression at 15.97%, anxiety at 15.5%, PTSD at 21.94%, and insomnia at 23.87% [41]—all far higher than usual [42].”
InfluentialMental health outcomes of the CoViD-19 pandemic
Talevi, D., Socci, V., Carai, M., Carnaghi, G., Faleri, S., Trebbi, E., di Bernardo, A., Capelli, F., & Pacitti, F. (2020) · Rivista di Psichiatria · doi:10.1708/3382.33569 · Cited by 821 · cited 1×
“…including but not limited to drug side effects, a fear of severe disease consequences, a fear of infecting others, and an inability to get correct information in a timely manner [13]—all of which may lead to several psychological distresses including anxiety, depression, and insomnia [8,14].”
The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis
Deng, J., Zhou, F., Hou, W., Silver, Z., Wong, C. Y., Chang, O., Huang, E., & Zuo, Q. K. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14506 · Cited by 771 · cited 1×
“Facing public health emergencies, people experiencing stress responses are likely to encounter mental health problems [39].”
Lam, M. H.-B. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.384 · Cited by 723
Norms for Zung’s Self-rating Anxiety Scale
Dunstan, D. A., & Scott, N. (2020) · BMC Psychiatry · doi:10.1186/s12888-019-2427-6 · Cited by 576 · cited 1×
“SAS [33] is also composed of 20 items and is rated on a 4-point Likert scale (from 1, “no or a little of the time,” to 4, “most of the time or all the time”).”
Parikh, S. V., Quilty, L. C., Ravitz, P., Rosenbluth, M., Pavlova, B., Grigoriadis, S., Velyvis, V., Kennedy, S. H., Lam, R. W., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659418 · Cited by 562
Psychological health, sleep quality, and coping styles to stress facing the COVID-19 in Wuhan, China
Fu, W., Wang, C., Zou, L., Guo, Y., Lu, Z., Yan, S., & Mao, J. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00913-3 · Cited by 389 · cited 2×
“Another research study obtained the opposite result, which reported that higher education levels were associated with sleep disorders [62].”
Gender Difference in the Prevalence of Insomnia: A Meta-Analysis of Observational Studies
Zeng, L.-N., Zong, Q.-Q., Yang, Y., Zhang, L., Xiang, Y.-F., Ng, C. H., Chen, L.-G., & Xiang, Y.-T. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.577429 · Cited by 360 · cited 1×
“A meta-analysis revealed the prevalence of insomnia in females was higher than that in males [60]; also, females were the predicted risk factor of insomnia during the COVID-19 pandemic [61,62].”
Self-citationWalter, H. J., Bukstein, O. G., Abright, A. R., Keable, H., Ramtekkar, U., Ripperger-Suhler, J., & Rockhill, C. (2020) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2020.05.005 · Cited by 335 · cited 1×
“It can be implied that the main mental health problems of patients with COVID-19 were depression, anxiety, and PTSD. Selective serotonin reuptake inhibitor antidepressants are the first-line drug treatment for depression, anxiety, and PTSD [44,45].”
Motter, J. N., Pimontel, M. A., Rindskopf, D., Devanand, D. P., Doraiswamy, P. M., & Sneed, J. R. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.09.022 · Cited by 303 · cited 1×
“…cCBT can be accessed with a computer, smartphone, or tablet without the need for face-to-face therapy, and this is especially key during a pandemic to reduce the risk of spreading infection [21]. cCBT does not require appointments, allowing instead for time flexibility and cost-effectiveness [22].”
Robinson, E., Titov, N., Andrews, G., McIntyre, K., Schwencke, G., & Solley, K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010942 · Cited by 277 · cited 1×
“There is substantial evidence that cCBT is an effective alternative to CBT for the treatment of mild to moderate depression and anxiety [18-20].”
Kaltenthaler, E., Sutcliffe, P., Parry, G., Beverley, C., Rees, A., & Ferriter, M. (2008) · Psychological Medicine · doi:10.1017/s0033291707002607 · Cited by 267 · cited 1×
“An effective method may be cognitive behavioral therapy (CBT), which is widely used to treat mild to moderate depression and anxiety [17].”
Internet-Based Cognitive-Behavioral Therapy for Depression: Current Progress and Future Directions
Webb, C. A., Rosso, I. M., & Rauch, S. L. (2017) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000139 · Cited by 217 · cited 1×
“…cCBT can be accessed with a computer, smartphone, or tablet without the need for face-to-face therapy, and this is especially key during a pandemic to reduce the risk of spreading infection [21]. cCBT does not require appointments, allowing instead for time flexibility and cost-effectiveness [22].”
Clarification of the cut-off score for Zung’s self-rating depression scale
Dunstan, D. A., & Scott, N. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2161-0 · Cited by 194 · cited 1×
“SDS [32] contains 20 items that reflect subjective feelings of depression.”
Early Adolescent Gender Differences in the Use of Ruminative and Distracting Coping Strategies
Broderick, P. C. (1998) · The Journal of Early Adolescence · doi:10.1177/0272431698018002003 · Cited by 182 · cited 1×
“Men tend to externalize their distress by directing action outward, while women tend to internalize their distress by directing action inward [26,27].”
The roles of sex, gender, and coping in adolescent depression.
Li, C. E., Digiuseppe, R. A., & Froh, J. J. (2006) · PubMed · Cited by 161
Li, J., Li, X., Jiang, J., Xu, X., Wu, J., Xu, Y., Lin, X., Hall, J., Xu, H., Xu, J., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.580827 · Cited by 157 · cited 1×
“Li et al [51] designed a randomized controlled trial to prove traditional CBT significantly decreased depression, anxiety, and stress symptoms in patients with COVID-19 [51].”
Self-citationSARS-CoV-2 and COVID-19: From the Bench to the Bedside
Romagnoli, S., Peris, A., Gaudio, A. R. D., & Geppetti, P. (2020) · Physiological Reviews · doi:10.1152/physrev.00020.2020 · Cited by 153 · cited 1×
“The COVID-19 epidemic is similar to SARS and MERS [8] but has spread more quickly and efficiently [9].”
Improving the Efficiency of Psychotherapy for Depression: Computer-Assisted Versus Standard CBT
Thase, M. E., Wright, J. H., Eells, T. D., Barrett, M. S., Wisniewski, S. R., Balasubramani, G. K., McCrone, P., & Brown, G. K. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17010089 · Cited by 131 · cited 1×
“There is substantial evidence that cCBT is an effective alternative to CBT for the treatment of mild to moderate depression and anxiety [18-20].”
Wahlund, T., Mataix-Cols, D., Olofsdotter Lauri, K., de Schipper, E., Ljótsson, B., Aspvall, K., & Andersson, E. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000512843 · Cited by 105 · cited 1×
“[53,54].”
Vallury, K. D., Jones, M., & Oosterbroek, C. (2015) · Journal of Medical Internet Research · doi:10.2196/jmir.4145 · Cited by 105 · cited 1×
“The privacy of patients is better protected, and the stigma of face-to-face therapy is mitigated [23].”
Twomey, C., O'Reilly, G., Byrne, M., Bury, M., White, A., Kissane, S., McMahon, A., & Clancy, N. (2014) · British Journal of Clinical Psychology · doi:10.1111/bjc.12055 · Cited by 100 · cited 1×
“In the 1-month follow-up, the results of our study still showed a significant improvement of the efficacy in the cCBT + TAU group, which was in accordance with previous research on cCBT relieving depression, anxiety, and insomnia symptoms in the short-term follow-up [55,56].”
Grist, R., & Cavanagh, K. (2013) · Journal of Contemporary Psychotherapy · doi:10.1007/s10879-013-9243-y · Cited by 100
Cheng, P., Casement, M. D., Kalmbach, D. A., Castelan, A. C., & Drake, C. L. (2021) · Sleep · doi:10.1093/sleep/zsaa258 · Cited by 97 · cited 1×
“[53,54].”
Anxiety and depression and its correlates in patients with coronavirus disease 2019 in Wuhan
Nie, X.-D., Wang, Q., Wang, M.-N., Zhao, S., Liu, L., Zhu, Y.-L., & Chen, H. (2021) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1791345 · Cited by 83 · cited 1×
“A cross-sectional study on psychological distress in patients with COVID-19 showed that the prevalence of symptoms of depression and anxiety was 35.9% and 38.5%, respectively [11].”
InfluentialSelf-citationEncyclopedia of health communication
(2014) · Choice Reviews Online · doi:10.5860/choice.185849 · Cited by 81
Qiu, J., Chen, W., Gao, X., Xu, Y., Tong, H., Yang, M., Xiao, Z., & Yang, M. (2013) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.3109/0167482x.2013.766791 · Cited by 76 · cited 1×
“However, some studies revealed that the efficacy of cCBT was no different from the control group after a long-term follow-up [57,58].”
Self-citationZhang, S. X., Wang, Y., Jahanshahi, A. A., Li, J., & Schmitt, V. G. H. (2021) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2021.110366 · Cited by 71 · cited 1×
“Females and relatively high educational level were found to be predictors of mental distress of adults 1 month in the COVID-19 epidemic [25].”
Self-citationGu, Y., Zhu, Y., Xu, F.-Z., Xi, J., & Xu, G. (2020) · Asia-Pacific Psychiatry · doi:10.1111/appy.12443 · Cited by 71
Rosso, I. M., Killgore, W. D. S., Olson, E. A., Webb, C. A., Fukunaga, R., Auerbach, R. P., Gogel, H., Buchholz, J. L., & Rauch, S. L. (2017) · Depression and Anxiety · doi:10.1002/da.22590 · Cited by 64
Ebola Virus Disease: A Review of Its Past and Present
Murray, M. J. (2015) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000000866 · Cited by 62 · cited 1×
“…effects of physical and psychological distress have increased with each successive public health emergency, such as with the severe acute respiratory syndrome (SARS) in 2003 [1], the Middle East Respiratory Syndrome (MERS) [2] in 2012, the Ebola virus disease in 2014 [3], and COVID-19 in 2020 [4].”
Ritvo, P., Knyahnytska, Y., Pirbaglou, M., Wang, W., Tomlinson, G., Zhao, H., Linklater, R., Bai, S., Kirk, M., Katz, J., et al. (2021) · Journal of Medical Internet Research · doi:10.2196/24380 · Cited by 48
Nakao, S., Nakagawa, A., Oguchi, Y., Mitsuda, D., Kato, N., Nakagawa, Y., Tamura, N., Kudo, Y., Abe, T., Hiyama, M., et al. (2018) · Journal of Medical Internet Research · doi:10.2196/10743 · Cited by 45 · cited 1×
“Additionally, based on the previous studies on such interventions for depressive or anxiety symptoms [35-38], we expected to achieve a value δ≥ 5 in the level of depressive and anxiety symptoms with the cCBT intervention.”
Bajaj, S., Blair, K. S., Schwartz, A., Dobbertin, M. D., & Blair, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243527 · Cited by 43 · cited 1×
“A meta-analysis revealed the prevalence of insomnia in females was higher than that in males [60]; also, females were the predicted risk factor of insomnia during the COVID-19 pandemic [61,62].”
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.1.foc128 · Cited by 38
Sato, D., Yoshinaga, N., Nagai, E., Nagai, K., & Shimizu, E. (2018) · Journal of Medical Internet Research · doi:10.2196/12686 · Cited by 34 · cited 1×
“In the 1-month follow-up, the results of our study still showed a significant improvement of the efficacy in the cCBT + TAU group, which was in accordance with previous research on cCBT relieving depression, anxiety, and insomnia symptoms in the short-term follow-up [55,56].”
Martínez, V., Rojas, G., Martínez, P., Gaete, J., Pedro Zitko, M., Vöhringer, P. A., & Araya, R. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00552 · Cited by 32 · cited 1×
“However, some studies revealed that the efficacy of cCBT was no different from the control group after a long-term follow-up [57,58].”
Alavi, N., Yang, M., Stephenson, C., Nikjoo, N., Malakouti, N., Layzell, G., Jagayat, J., Shirazi, A., Groll, D., Omrani, M., et al. (2020) · JMIR Research Protocols · doi:10.2196/24913 · Cited by 27 · cited 1×
“However, administering CBT effectively using face-to-face techniques is very time-consuming and costly, and is unavailable to most patients in isolation [52].”
Drug Interactions of Psychiatric and COVID-19 Medications
Mohebbi, N., Talebi, A., Moghadamnia, M., Nazari, Z., & Shakiba, A. (2020) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.11.covid19.2500.1 · Cited by 26 · cited 1×
“Further, a review indicated there is a great potential for drug-to-drug interactions between antiretroviral drugs and psychotropics, especially antidepressants and anxiolytics, which could hinder treatment efficacy or even produce life-threatening adverse drug reactions [48].”
Treatment of Depression: Men and Women Are Different?
Weissman, M. M. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13121668 · Cited by 25 · cited 1×
“Such gender difference may influence the treatment response [28].”
Khan, S., Siddique, R., Xiaoyan, W., Zhang, R., Nabi, G., Afzal, M. S., Liu, J., & Xue, M. (2020) · Brain and Behavior · doi:10.1002/brb3.1901 · Cited by 23 · cited 1×
“The pandemic has increased the risk of psychological disorders, especially in confirmed cases of COVID-19 [40].”
dos Santos, É. N., Molina, M. L., Mondin, T. C., Cardoso, T. D. A., da Silva, R. A., Souza, L. D. D. M., & Jansen, K. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112804 · Cited by 13
Guandalini, L. S., da Silva, E. F., Lopes, J. D. L., Santos, V. B., Lopes, C. T., & de Barros, A. L. B. L. (2020) · International Journal of Nursing Sciences · doi:10.1016/j.ijnss.2020.09.003 · Cited by 10 · cited 1×
“Compared to the TAU group, insomnia symptoms were not improved significantly in female patients and those with middle school education treated by cCBT. Previous studies indicated that females were a high-risk population for insomnia [59].”
Yuan, M., Ren, Z., Zhu, H., Zhang, Y., Meng, Y., & Zhang, W. (2016) · PubMed · Cited by 5
A national survey of residual symptoms in Chinese depressive patients after acute phase treatment
Xiao, L., Feng, L., Zhu, X., Wang, G., Wu, W., Hu, Y., Niu, Y., Hu, J., Wang, X., Gao, C., et al. (2017) · Chin J Psychiatry · doi:10.3760/cma.j.issn.1006-7884.2017.03.005 · Cited by 5 · cited 1×
“Moreover, only an approximate 33% of the patients were clinically cured [46], and these demonstrated residual symptoms following acute treatment [47].”
Research works printed but not linked: 5
- Bisson, JI, 2010, BMJ Clin Evid, 2010, 1005
- Li, CE, 2006, Adolescence, 41, 409
- Yuan, M, 2016, Sichuan Da Xue Xue Bao Yi Xue Ban, 47, 898
- 10.13798/j.issn.1009-153x.2020.08.011 · doi:10.13798/j.issn.1009-153x.2020.08.011
- 10.3969/j.issn.2095-8552.2020.11.028 · doi:10.3969/j.issn.2095-8552.2020.11.028
Cited by
Depression and Anxiety During the COVID-19 Pandemic: Epidemiology, Mechanism, and Treatment
Zhu, C., Zhang, T., Li, Q., Chen, X., & Wang, K. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00970-2 · Cited by 185
“Recent studies have shown that CBT was effective at relieving depressive and anxiety symptoms in patients with COVID-19 [75, 84, 85].”
BackgroundKim, J., Aryee, L. M. D., Bang, H., Prajogo, S., Choi, Y. K., Hoch, J. S., & Prado, E. L. (2023) · JMIR Mental Health · doi:10.2196/43066 · Cited by 106
“More information about the included studies is available in Multimedia Appendix 6 [26-121].”
BackgroundInfluentialEfficacy of Pulmonary Rehabilitation in Post-COVID-19: A Systematic Review and Meta-Analysis
Oliva, E. M., Martínez‐Pozas, O., Cuenca‐Zaldívar, J. N., Villafañe, J. H., Jiménez‐Ortega, L., & Romero, E. A. S. (2023) · Biomedicines · doi:10.3390/biomedicines11082213 · Cited by 88
“However, considering that mental health disorders in patients with COVID-19 showed prevalence rates of 16% in terms of depression or 15% in terms of anxiety [82], and seeing that psychological therapies such as cognitive behavioral therapy had shown positive effects improving anxiety and depression in patients with CO…”
Wang, Y., Li, X., Zhang, Q., Yeung, D. Y.-L., & Wu, Y. (2025) · JMIR mhealth and uhealth · doi:10.2196/63806 · Cited by 76
Self-citationKomariah, M., Amirah, S., Faisal, E. G., Prayogo, S. A., Maulana, S., Platini, H., Suryani, S., Yosep, I., & Arifin, H. (2022) · Healthcare · doi:10.3390/healthcare10071224 · Cited by 70
“(2021) [34] China RCT 326 Female (102) Male(150) IG: 43.”
Metadata
- Authors
- Liu, Z., Qiao, D., Xu, Y., Zhao, W., Yang, Y., Wen, D., Li, X., Nie, X., Dong, Y., Tang, S., Jiang, Y., Wang, Y., Zhao, J., & Xu, Y.
- Affiliations
- Shanxi Medical University (CN)
- Chongqing Public Health Medical Center (CN)
- Chongqing University (CN)
- Corresponding author
- Xu, Yong
- ORCID
- Venue
- Journal of Medical Internet Research
- Publisher
- JMIR Publications Inc.
- Published
- 2021-05-14
- Volume
- 23
- Issue
- 5
- Pages
- e26883
- ISSN
- 1438-8871 (ISSN-L)
- PMC
- PMC8128049
- OpenAlex
- W3159534035
- Cited by
- 169
- References
- 61
- Citations by year
- 2026: 9 · 2025: 40 · 2024: 29 · 2023: 51 · 2022: 31 · 2021: 9
- FWCI
- 26.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Medical Internet Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81601193)
- Shanxi Scholarship Council of China (2015-100)
- Shanxi Medical University (YC1409)
- Shanxi Province Science Foundation for Youths (2015021204)
- Topics
- Social Sciences › Psychology › Applied Psychology › Digital Mental Health Interventions
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › COVID-19 and Mental Health
- Keywords
- computerized cognitive behavioral therapy, COVID-19 pandemic, depressive symptoms, anxiety symptoms, insomnia, psychological intervention, antiretroviral drugs, antidepressant drug interactions, usual care, Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Zung Self-Rating Depression Scale, Self-Rating Anxiety Scale, Athens Insomnia Scale, sex differences, educational attainment, follow-up outcomes, COVID-19 patients
- MeSH terms
- COVID-19, SARS-CoV-2, Adult, Anxiety, Depression, Female, Humans, Male, Prospective Studies, Cognitive Behavioral Therapy, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
